Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 61Active not recruiting 27Recruiting 18Terminated 17Withdrawn 11Unknown 7Enrolling by invitation 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1

Conditions

Prostatic Neoplasms, Castration-Resistant 1Neoplasms 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cytarabine 3venetoclax 2fludarabine 2olverembatinib 1ibrutinib 1fludarabine phosphate 1decitabine and cedazuridine drug combination 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Surveys and Questionnaires 1Ropivacaine 1Platelet Transfusion 1Melphalan 1Maintenance 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Lenalidomide 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Imatinib Mesylate 1Dexamethasone 1Daunorubicin 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × ibrutinib × Other hematologic neoplasm × Clear all
NCT06788509 2026-06-05

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

Janssen Research & Development, LLC

Phase 1 Enrolling by invitation
120 enrolled
GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡